Margins matter. The more Immucor
Here's the current margin snapshot for Immucor and some of its sector and industry peers and direct competitors.
Company |
TTM Gross Margin |
TTM Operating Margin |
TTM Net Margin |
---|---|---|---|
Immucor |
70.9% |
38.6% |
25.1% |
Gen-Probe |
68.2% |
26.2% |
19.0% |
Meridian Bioscience |
62.0% |
29.8% |
18.6% |
Haemonetics |
52.4% |
16.7% |
9.3% |
Source: Capital IQ, a division of Standard & Poor's. TTM = trailing 12 months.
Unfortunately, that table doesn't tell us much about where Immucor has been, or where it's going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it can't make up for this problem by cutting costs -- and most companies can't -- then both the business and its shares face a decidedly bleak outlook.
Of course, over the short term, the kind of economic shocks we recently experienced can drastically affect a company's profitability. That's why I like to look at five fiscal years' worth of margins, along with the results for the trailing 12 months (TTM), the latest fiscal year, and the latest fiscal quarter (LFQ). You can't always reach a hard conclusion about your company's health, but you can better understand what to expect, and what to watch.
Here's the margin picture for Immucor over the past few years.
Source: Capital IQ, a division of Standard & Poor's. Dollar amounts in millions. FY= fiscal year. TTM = trailing 12 months.
(Because of seasonality in some businesses, the numbers for the last period on the right -- the TTM figures -- aren't always comparable to the FY results preceding them.)
Here's how the stats break down:
- Over the past five years, gross margin peaked at 71.9% and averaged 70.1%. Operating margin peaked at 41.5% and averaged 39.3%. Net margin peaked at 27.4% and averaged 25.3%.
- TTM gross margin is 70.9%, 80 basis points better than the five-year average. TTM operating margin is 38.6%, 70 basis points worse than the five-year average. TTM net margin is 25.1%, 20 basis points worse than the five-year average.
With recent TTM operating and net margins below historical averages, Immucor has some work to do.
If you take the time to read past the headlines and crack a filing now and then, you're probably ahead of 95% of the market's individual investors. To stay ahead, learn more about how I use analysis like this to help me uncover the best returns in the stock market. Got an opinion on the margins at Immucor? Let us know in the comments below.
- Add Immucor to My Watchlist.
- Add Gen-Probe to My Watchlist.
- Add Meridian Bioscience to My Watchlist.
- Add Haemonetics to My Watchlist.